IL157693A0 - Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist - Google Patents

Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

Info

Publication number
IL157693A0
IL157693A0 IL15769302A IL15769302A IL157693A0 IL 157693 A0 IL157693 A0 IL 157693A0 IL 15769302 A IL15769302 A IL 15769302A IL 15769302 A IL15769302 A IL 15769302A IL 157693 A0 IL157693 A0 IL 157693A0
Authority
IL
Israel
Prior art keywords
receptor antagonist
vascular endothelial
factor receptor
inhibiting tumor
combination methods
Prior art date
Application number
IL15769302A
Other languages
English (en)
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of IL157693A0 publication Critical patent/IL157693A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15769302A 2001-03-02 2002-03-04 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist IL157693A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/798,689 US6811779B2 (en) 1994-02-10 2001-03-02 Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
PCT/US2002/006762 WO2002070008A1 (en) 2001-03-02 2002-03-04 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

Publications (1)

Publication Number Publication Date
IL157693A0 true IL157693A0 (en) 2004-03-28

Family

ID=25174032

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15769302A IL157693A0 (en) 2001-03-02 2002-03-04 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

Country Status (17)

Country Link
US (1) US6811779B2 (es)
EP (1) EP1379276A4 (es)
JP (1) JP2005506288A (es)
KR (1) KR20040023590A (es)
BG (1) BG108214A (es)
BR (1) BR0207977A (es)
CA (1) CA2439933A1 (es)
CZ (1) CZ20032586A3 (es)
EE (1) EE200300428A (es)
HU (1) HUP0303378A2 (es)
IL (1) IL157693A0 (es)
MX (1) MXPA03007909A (es)
NO (1) NO20033856L (es)
PL (1) PL364719A1 (es)
RU (1) RU2003129228A (es)
WO (1) WO2002070008A1 (es)
ZA (1) ZA200307682B (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999037751A1 (en) * 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
US7018371B2 (en) * 2001-05-07 2006-03-28 Xoft, Inc. Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia
JP2005508298A (ja) * 2001-06-20 2005-03-31 イムクローン システムズ インコーポレイティド アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
US20040241160A1 (en) * 2001-07-13 2004-12-02 Yan Wu Vegfr-1 antibodies to treat breast cancer
US20050026220A1 (en) * 2001-08-10 2005-02-03 Shahin Rafii Isolation and mobilization of stem cells expressing vegfr-1
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068155A2 (en) * 2002-02-12 2003-08-21 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
CN100457181C (zh) * 2002-03-04 2009-02-04 伊姆克罗尼系统公司 用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法
JP2005526506A (ja) * 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的なヒト抗体及びその利用
US20050186204A1 (en) * 2002-06-28 2005-08-25 Peter Carmeliet Use of antibodies against FLT-1 for the treatment of osteoporosis
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1572131B1 (en) * 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
CA2506320A1 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1473043A1 (en) * 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
AU2013200394B2 (en) * 2003-07-23 2015-07-09 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
ES2297490T3 (es) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050027196A1 (en) * 2003-07-30 2005-02-03 Fitzgerald Loretta A. System for processing patient radiation treatment data
US20050196340A1 (en) * 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
CA2534197A1 (en) * 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
US7683172B2 (en) * 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
EP1735348B1 (en) * 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
JP2007531728A (ja) * 2004-04-02 2007-11-08 アドベントルクス ファーマシューティカルズ， インコーポレイテッド 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用
RU2006146625A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr)
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
WO2006030826A1 (ja) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
EP2377555A3 (en) * 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
JP5202956B2 (ja) * 2004-11-19 2013-06-05 コーネル リサーチ ファンデーション インコーポレーティッド 癌の治療およびモニタリングならびに化学療法薬に関するスクリーニングにおける血管内皮増殖因子受容体１＋細胞の使用法
WO2006083355A2 (en) * 2004-11-19 2006-08-10 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
US20060160157A1 (en) * 2005-01-19 2006-07-20 Zuckerman Mathew M Method, compositions and classification for tumor diagnostics and treatment
BRPI0518104B8 (pt) * 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
UA95902C2 (ru) * 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
CN102512281A (zh) * 2005-11-15 2012-06-27 内奥维斯塔公司 用于眼内近距离治疗的方法和器具
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008026748A1 (fr) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
CN101600694A (zh) * 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
EP2139921A2 (en) 2007-04-17 2010-01-06 Imclone LLC PDGFRbeta-SPECIFIC INHIBITORS
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
PL2631248T3 (pl) 2007-06-15 2018-06-29 Medigene Ag Leczenie nowotworów z użyciem specyficznego przeciwciała anty-L1
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2713930A1 (en) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US8642515B2 (en) 2009-09-04 2014-02-04 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014110261A1 (en) 2013-01-11 2014-07-17 Massachusetts Eye And Ear Infirmary Cyp450 lipid metabolites reduce inflammation and angiogenesis
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016168159A1 (en) * 2015-04-14 2016-10-20 Academia Sinica Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN106892980B (zh) * 2017-01-25 2020-08-04 长春金赛药业有限责任公司 抗vegfr2单克隆抗体及其应用
CN110959014B (zh) * 2017-07-18 2024-01-16 协和麒麟株式会社 抗人ccr1单克隆抗体
WO2020198074A1 (en) 2019-03-22 2020-10-01 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US301299A (en) 1884-07-01 Vehicle-spring
US2132498A (en) 1936-07-22 1938-10-11 Smith Roller bit
KR870008714A (ko) 1986-03-07 1987-10-20 사까이 유미 도광섬유 조명장치
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE4003229A1 (de) 1990-02-03 1991-08-08 Bosch Gmbh Robert Elektromagnetisch betaetigbares ventil
DE69232718T2 (de) 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
AU3236793A (en) 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
CA2085291A1 (en) 1992-07-30 1994-01-31 Martin L. Breitman Novel receptor tyrosine kinase
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
EP0669988B2 (en) 1992-10-29 2009-07-08 The Australian National University Angiogenesis inhibitory antibodies
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH07131958A (ja) 1993-11-04 1995-05-19 Odawara Eng:Kk ステータ巻線機
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
AUPM379394A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - i
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
WO1997027199A1 (en) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
JP2000512990A (ja) 1996-06-24 2000-10-03 ファイザー・インク 過増殖性疾患を処置するためのフェニルアミノ置換三環式誘導体
EP0882799B1 (en) 1996-11-21 2006-06-28 Kyowa Hakko Kogyo Kabushiki Kaisha Anti-human vegf receptor flt-1 monoclonal antibody
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
EP1117659B1 (en) 1998-09-29 2003-12-03 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
NZ527718A (en) 1998-11-19 2004-11-26 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents

Also Published As

Publication number Publication date
CZ20032586A3 (cs) 2004-08-18
US20030103973A1 (en) 2003-06-05
HUP0303378A2 (hu) 2003-12-29
NO20033856L (no) 2003-11-03
EP1379276A4 (en) 2004-06-30
JP2005506288A (ja) 2005-03-03
EE200300428A (et) 2004-10-15
RU2003129228A (ru) 2005-03-10
CA2439933A1 (en) 2002-09-12
MXPA03007909A (es) 2005-06-03
BG108214A (en) 2004-09-30
NO20033856D0 (no) 2003-09-01
EP1379276A1 (en) 2004-01-14
KR20040023590A (ko) 2004-03-18
ZA200307682B (en) 2005-01-13
US6811779B2 (en) 2004-11-02
PL364719A1 (en) 2004-12-13
WO2002070008A1 (en) 2002-09-12
BR0207977A (pt) 2005-02-01

Similar Documents

Publication Publication Date Title
IL157693A0 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
EP1487490A4 (en) COMBINATION OF TUMOR GROWTH INHIBITION METHODS USING A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONIST
IL176135A0 (en) Inhibitors of type 2 vascular endothelial growth factor receptors
EP1385862A4 (en) VASCULAR ENDOTHEL GROWTH FACTOR 2
HK1115302A1 (en) Antibodies against vascular endothelial growth factor receptor-1
EP1699484A4 (en) HUMANIZED ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR
AU2003297128A8 (en) Vascular suturing clip
AU2001228742A1 (en) Ligand for vascular endothelial growth factor receptor
HK1092804A1 (en) New quinazoline derivatives
AU7860901A (en) Quinazoline derivatives
HUP0202713A3 (en) Pteridinones as kinase inhibitors
HU0003386D0 (en) Use of crf antagonists
AU2002353081A1 (en) Pulsatile release histamine h2 antagonist dosage forms
GB2395506B (en) Liner hanger
EP1313512A4 (en) LIKE ENDOTH GROWTH FACTOR 2 (VEGF-2)
AU5023300A (en) Vascular endothelial growth factor variants
HK1063791A1 (en) Nk1 antagonists
AU2003216389A8 (en) Induction of hair growth with vascular endothelial growth factor
IL151992A0 (en) Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
GB0031832D0 (en) Metal section for street furniture structures
EP1221963A4 (en) METHODS OF INHIBITING OSTEOCLASTOGENESIS
AU2003273702A8 (en) Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor
GB2356343B (en) Ornamental pool liner
GB9907826D0 (en) Fence pot support
CA94279S (en) Soup bowl